Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $12.57 Consensus PT from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) has received a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.57.

A number of equities research analysts have recently commented on the stock. Chardan Capital lifted their price target on shares of Voyager Therapeutics from $4.00 to $6.00 in a report on Wednesday, March 9th. StockNews.com assumed coverage on shares of Voyager Therapeutics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Saturday, March 12th. Finally, UBS Group reduced their price target on shares of Voyager Therapeutics from $14.00 to $6.00 in a research report on Monday, January 3rd.

In other news, COO Robin Swartz sold 4,413 shares of the business’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of $8.29, for a total transaction of $36,583.77. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Robert W. Hesslein sold 4,955 shares of the business’s stock in a transaction on Monday, March 21st. The stock was sold at an average price of $8.29, for a total transaction of $41,076.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,933 shares of company stock worth $124,170. 25.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Voyager Therapeutics in the fourth quarter valued at $28,000. Marshall Wace LLP acquired a new stake in Voyager Therapeutics in the fourth quarter valued at $1,195,000. Millennium Management LLC raised its holdings in Voyager Therapeutics by 54.8% in the fourth quarter. Millennium Management LLC now owns 423,058 shares of the company’s stock valued at $1,146,000 after acquiring an additional 149,698 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics during the fourth quarter valued at $56,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in Voyager Therapeutics during the fourth quarter valued at $797,000. 63.55% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ VYGR opened at $8.92 on Friday. The company has a market cap of $339.99 million, a PE ratio of -4.69 and a beta of 1.13. Voyager Therapeutics has a 12 month low of $2.46 and a 12 month high of $9.74. The company has a 50-day simple moving average of $6.20 and a 200-day simple moving average of $4.27.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last issued its quarterly earnings results on Tuesday, March 8th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.51. The business had revenue of $28.07 million during the quarter, compared to the consensus estimate of $31.45 million. Voyager Therapeutics had a negative net margin of 190.30% and a negative return on equity of 66.35%. As a group, analysts expect that Voyager Therapeutics will post -1.35 EPS for the current fiscal year.

About Voyager Therapeutics (Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Recommended Stories